阿昔替尼治疗转移性肾细胞癌在大型综合癌症中心的前瞻性真实世界经验
在法国古斯塔夫·鲁西癌症中心前瞻性评估2012至2015年接受阿昔替尼二线或更后线治疗的160例转移性肾细胞癌患者,客观缓解率为32%(均为部分缓解),中位无进展生存期、治疗失败时间和总生存期分别为8.3、5.8和16.4个月,高血压为最常见不良事件(3级39%、4级2%)。
要点
- 160例转移性肾细胞癌患者中40%接受二线、60%接受更后线阿昔替尼治疗。
- 客观缓解率32%(n=33,均为部分缓解),中位无进展生存期8.3个月、总生存期16.4个月。
- 高血压最常见,3级39%、4级2%;IMDC风险分组和2周剂量滴定与客观缓解率相关。
核心结论
- 阿昔替尼在常规实践中的疗效与既往报告相似,不仅限于二线,在更后线治疗中亦然。
研究设计与样本
- 2012至2015年在古斯塔夫·鲁西癌症中心开展的前瞻性评估,纳入接受阿昔替尼二线或更后线治疗的转移性肾细胞癌患者160例。
主要发现
- 160例患者中接受二线治疗者占40%,接受更后线治疗者占60%。
- IMDC风险分组为良好、中等和差者分别占13%、54%和32%。
- 剂量滴定至7 mg每日两次者占38%,至10 mg每日两次者占19%。
- 客观缓解率为32%(n=33,均为部分缓解);中位无进展生存期8.3个月,中位治疗失败时间5.8个月,中位总生存期16.4个月。
- 高血压为最常见不良事件,3级占39%,4级占2%;IMDC风险分组和2周时剂量滴定与客观缓解率相关,3级高血压与之呈边缘相关;IMDC风险分组和3级高血压与更好的无进展生存期、治疗失败时间和总生存期显著相关,2周时剂量滴定与无进展生存期和治疗失败时间相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Axitinib has shown activity in metastatic renal cell carcinoma (mRCC) in a large phase III clinical trial and was approved in patients who failed first-line therapy. This drug has been available in France since November 2012. The objective is to report efficacy and safety of axitinib in mRCC outside of clinical trials. METHODS: A prospective evaluation of mRCC patients treated by axitinib in second or further next-line therapy at Gustave Roussy was conducted from 2012 to 2015. Objective response rate (ORR), progression-free survival (PFS), time to treatment failure (TTF), overall survival (OS) and toxicities were analysed. The correlation between clinical markers and ORR, PFS, TTF and OS were explored. RESULTS: One-hundred and sixty patients with mRCC, received axitinib in second (40%) or further next-line therapy (60%). International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk group classification was good, intermediate and poor in 13%, 54% and 32%, respectively. Dose titration (DT) to 7 mg twice a day (bid) was performed in 38% and to 10 mg bid in 19% of the patients. Hypertension was the most common adverse event, (grade (G)3: 39%; G4: 2%). ORR occurred in 32% (n = 33, only partial response). Median PFS, TTF and OS were 8.3, 5.8 and 16.4 months, respectively. IMDC risk group and DT at 2 weeks are associated to ORR while grade 3 hypertension is marginally associated. IMDC risk group and grade 3 hypertension are significantly associated with better PFS, TTF and OS while DT at 2 weeks is associated to PFS and TTF. CONCLUSION: Efficacy of axitinib in routine practice is similar to that previously reported, not only in second- but also in further next-lines of therapy.
引用
- Matias M, Le Teuff G, Albiges L, et al. Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre. Eur J Cancer. 2017. PMID: 28511146. doi:10.1016/j.ejca.2017.04.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。